Tavalisse FDA Approval History
FDA Approved: Yes (First approved April 17, 2018)
Brand name: Tavalisse
Generic name: fostamatinib
Dosage form: Tablets
Company: Rigel Pharmaceuticals, Inc.
Treatment for: Idiopathic Thrombocytopenic Purpura
Tavalisse (fostamatinib) is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of patients with chronic immune thrombocytopenia (ITP).
Development Timeline for Tavalisse
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.